Type 2 diabetes.
Conditions
Interventions
First intervention group: empagliflozin-linagliptin drug 5-10 mg daily and one tablet per day for three months. The second intervention group: dapagliflozin-linagliptin 5-10 mg daily, one tablet per d
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Inclusion criteria
Inclusion criteria: Having type 2 diabetes Hb A1c above 7 and below 11 No acute hospitalization conditions Age between 30 and 75 years Patients with albuminuria Not taking the drug beforehand
Exclusion criteria
Exclusion criteria: Acute hospitalization conditions Pre-medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main outcome of this study is urine microalbuminuria, which is considered as the main indicator of diabetic nephropathy, LDL and HbA1c. This result is evaluated by spot urine and blood samples at the beginning of the study, three months after the start of the treatment. Timepoint: At the beginning of the study and three months after the start of treatment. Method of measurement: It is evaluated by spot urine and blood samples at the beginning of the study and three months after the start of the treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Other outcomes included in the researcher's checklist (attached at the end of the proposal), such as FBS, GFR, and lipid profile, are evaluated by the patient's blood test at the beginning of the study, and after the completion of the treatment period, i.e., three months after the start of the treatment. Timepoint: The beginning of the study and three months after the start of treatment. Method of measurement: By testing the patient's blood. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaeed seyedi niasar
Arak University of Medical Sciences
Outcome results
None listed